Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupMEDGF 93 EPS without NRI is $4.74 as of Dec. 2025. GuruFocus rates MEDGF with a GF Score™ of 93/100 and a GF Value™ of $100.71. The stock has 2 warning signs investors should review. Among 663 Medical Devices & Instruments companies, Medacta Group ranks better than 63.5% on this metric.
Medacta Group's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was $1.96.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $4.74.
During the past 12 months, Medacta Group's average earnings per share (NRI) Growth Rate was 8.40% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 18.60% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 12.40% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Medacta Group's EPS without NRI or its related term are showing as below:
MEDGF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -32.6 Med: 3.8 Max: 51.9
Current: 18.6
During the past 11 years, Medacta Group's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 51.90% per year. The lowest was -32.60% per year. And the median was 3.80% per year.
MEDGF's 3-Year EPS without NRI Growth Rate is ranked better than 63.5% of 663
companies
in the Medical Devices & Instruments industry
Industry Median: 8.1
vs MEDGF: 18.60
Medacta Group's EPS (Diluted) for the
six
months ended in Dec. 2025 was $2.07.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $5.55.
Medacta Group's EPS (Basic) for the
six
months ended in Dec. 2025 was $2.08.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $5.56.
Medacta Group (OTCPK:MEDGF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Medacta Group EPS without NRI Related Terms
Medacta Group EPS without NRI Historical Data
* Premium members only.
The historical data trend for Medacta Group's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDGF vs ABT, SYK, MDT: EPS without NRI Comparison
For the Medical Devices subindustry, Medacta Group's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Medacta Group's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $4.74
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medacta Group (MEDGF) has a EPS without NRI of $4.74 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Medacta Group and its competitors. According to the industry distribution chart, Medacta Group ranks #242 out of 663 companies in the Medical Devices & Instruments industry, placing it in the top 36.5%.
Is Medacta Group's EPS without NRI too high?
Medacta Group's current EPS without NRI is $4.74. The Medical Devices & Instruments industry median EPS without NRI is 8.10. Medacta Group's value of $4.74 is 41.5% below this industry median. Based on the distribution chart, Medacta Group ranks #242 out of 663 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medacta Group has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's EPS without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #242 out of 663 companies for EPS without NRI. This puts Medacta Group in the upper half of its industry. The industry median EPS without NRI is 8.10. Medacta Group's value of $4.74 is 41.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.10, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current EPS without NRI of $4.74 is 41.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Medacta Group and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current EPS without NRI is $4.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Medacta Group (MEDGF) has a current EPS without NRI of $4.74. The stock's GF Value™ is $100.71, compared to a current price of $83.91 — trading 16.7% below its estimated fair value. The current EPS without NRI is $4.74 and 41.5% below the Medical Devices & Instruments industry median of 8.10. Medacta Group's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Medacta Group (MEDGF), the current EPS without NRI is $4.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (MEDGF) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued.
The current stock price of $83.91 is trading 16.7% below its estimated GF Value™ of $100.71.
Key valuation signals for MEDGF:
EPS without NRI: $4.74
GF Value™: $100.71 vs. price of $83.91 (16.7% below fair value)
Industry Position: 41.5% below the Medical Devices & Instruments median (#242 of 663)
No single metric tells the full story. See the MEDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
93GF Score
Get the complete analysis for MEDGF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDGF has been successfully added to your 
